Skyrizi is a prescription drug that treats plaque psoriasis, psoriatic arthritis, and Crohn's disease. Learn how Skyrizi works and how long it takes to start working.

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...

The FDA has given its okay to the biologic drug Skyrizi (risankizumab) as a treatment for people with moderately to severely active ulcerative colitis. The medication works by blocking the immune ...

AbbVie already shared last month that its Skyrizi had trounced Johnson & Johnson’s rival biologic drug Stelara in Crohn’s disease. Now, detailed trial results show just how decisive Skyrizi ...

AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI®, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg ...

The regulatory filing seeks approval for Skyrizi, both as a 600mg intravenous (IV) induction and a 360mg subcutaneous (SC) maintenance therapy in patients aged 16 years and older with CD, who have ...

European Commission approves AbbVie’s Skyrizi to treat moderate to severe active Crohn's disease North Chicago, Illinois Thursday, November 24, 2022, 09:00 Hrs [IST] AbbVie announced the European ...

In another boost for AbbVie (NYSE: ABBV), the European Commission (EC) has granted a third approval of Skyrizi (risankizumab, 600mg intravenous [IV] induction and 360mg subcutaneous [SC] for ...

AbbVie’s Skyrizi (risankizumab) has been approved by the European Commission (EC) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately-to-severely active ...

AbbVie announced the European Commission approved SKYRIZI® as the first specific interleukin-23 inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had ...